ArticleEinstein (Sao Paulo, Brazil)2026

Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression.

Caroline Dotto Amarger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.